The reiteration of a Speculative Buy rating and maintenance of an $8 price target by Benchmark analyst Robert Wasserman indicates a positive outlook for Anebulo Pharmaceuticals. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.